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ABSTRACT
Response gene to complement-32 (RGC-32) acti-
vates cyclin-dependent kinase 1, regulates the cell
cycle and is deregulated in many human tumours.
We previously showed that RGC-32 expression is
upregulated by the cancer-associated Epstein-Barr
virus (EBV) in latently infected B cells through the
relief of translational repression. We now show that
EBV infection of naı¨ve primary B cells also induces
RGC-32 protein translation. In EBV-immortalised cell
lines, we found that RGC-32 depletion resulted in cell
death, indicating a key role in B cell survival. Study-
ing RGC-32 translational control in EBV-infected
cells, we found that the RGC-32 3′untranslated re-
gion (3′UTR) mediates translational repression. Re-
pression was dependent on a single Pumilio binding
element (PBE) adjacent to the polyadenylation sig-
nal. Mutation of this PBE did not affect mRNA cleav-
age, but resulted in increased polyA tail length. Con-
sistent with Pumilio-dependent recruitment of dead-
enylases, we found that depletion of Pumilio in EBV-
infected cells increased RGC-32 protein expression
and polyA tail length. The extent of Pumilio binding to
the endogenous RGC-32 mRNA in EBV-infected cell
lines also correlated with RGC-32 protein expression.
Our data demonstrate the importance of RGC-32 for
the survival of EBV-immortalised B cells and identify
Pumilio as a key regulator of RGC-32 translation.
INTRODUCTION
RGC-32 (RGCC, C13ORF15) was first described as a gene
induced by cell-cycle activation on exposure of rat oligo-
dendrocytes and human aortic endothelial cells to sub-lytic
doses of complement C5b9 (1,2). RGC-32 mRNA is ex-
pressed in most tissues and is upregulated at the RNA or
protein level in tumours of the colon, prostate, bladder,
breast, lung and ovaries (3–6). Conversely, RGC-32 is si-
lenced or downregulated in other tumour contexts includ-
ing multiple myeloma and glioblastoma (7,8). RGC-32 is
involved in many cell-type specific processes including an-
giogenesis, glucose homeostasis, macrophage phagocytosis
and T cell growth (9–12). RGC-32 knock-out mice develop
normally but are smaller than wild-type littermates due to
impaired placental angiogenesis (10). These mice also have
reduced adipose tissue mass and as a result, are protected
from diet-induced obesity and insulin resistance normally
associated with increased RGC-32 expression in these tis-
sues (13). RGC-32 has no homology to other human pro-
teins, but has been shown to be a binding partner and sub-
strate of cyclin-dependent kinase 1 (CDK1), polo-like ki-
nase 1 (PLK1) and Akt and is centrosome-associated dur-
ing mitosis (1,7,14). In vitro studies have demonstrated that
RGC-32 binding to CDK1 increases CDK1 activity in a
manner dependent on phosphorylation of threonine 91 in
a CDK phosphorylation consensus motif in RGC-32 (14).
Consistent with a cell-cycle regulatory function, expression
of RGC-32 in smooth muscle cells following G1 arrest pro-
motes S- and M-phase entry (14). Knock-down of RGC-32
also prevents complement and growth factor-induced cell-
cycle entry and CDK1 activation in aortic endothelial cells
(1).
We previously showed that RGC-32 protein is differen-
tially expressed in B cell-lines infected by Epstein-Barr virus
(EBV), with its expression depending on the viral gene ex-
pression profile of the infected cells (15). EBV is a her-
pesvirus associated with multiple malignancies including
Burkitt’s, Hodgkin’s and post-transplant lymphoma and
nasopharyngeal and gastric carcinoma. The virus immor-
talises B cells and establishes a latent infection in these
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cells. Initial B cell growth transformation results in the ex-
pression of all EBV latent proteins including six EBV nu-
clear antigens (EBNAs) and three latent membrane pro-
teins (LMPs). This pattern of latent gene expression is re-
ferred to as latency III and is the pattern of latent gene ex-
pression observed in EBV-infected lymphoblastoid cell lines
(LCLs) generated in vitro. In vivo, growth transformedEBV-
infected cells displaying the latency III pattern of gene ex-
pression successively downregulate their viral gene expres-
sion profile to more restricted patterns of gene expression
known as latency II and latency I. This allows infected cells
to transit through the B cell differentiation pathway and es-
tablish viral persistence in memory B cells. This spectrum
of latent gene expression patterns is also observed in EBV-
associated tumours, presumably reflecting the different ori-
gins of the malignant cells. RGC-32 protein expression was
only detected in EBV-infected cell lines that displayed the
latency III pattern of gene expression, and not in EBV neg-
ative cell lines or cell lines displaying the more restricted
latency I pattern of gene expression (15), indicating that
RGC-32 expression may be associated with initial growth
transformation by EBV.
RGC-32 protein expression was also induced when la-
tency III cell lines were created by infecting EBV-negative
lymphoma cell-lines with EBV (15). Interestingly, RGC-32
protein expression did not correlate with RGC-32 mRNA
expression in these different B cell lines. High-levels of
RGC-32 mRNA were present in cells with no detectable
RGC-32 protein and in cells expressing RGC-32 protein,
mRNA levels were extremely low (15). In both situations,
we found that RGC-32mRNAwas associated withmultiple
ribosomes, indicating that a post-initiation translational re-
pression mechanism was responsible for suppressing RGC-
32 protein production in EBV negative and latency I cell
lines (15). Given the potent transforming ability of EBV and
the well-documented disruption of cell-cycle regulation by
EBV latent genes at multiple potential points (16,17), we
postulated that upregulation of RGC-32 by EBV could con-
tribute to growth deregulation in infected cells. In support
of this theory, and consistent with previous reports of the ef-
fects of RGC-32 on cell-cycle regulation, we demonstrated
that overexpression of RGC-32 in B cell lines resulted in dis-
ruption of the G2/M checkpoint (15).
Translational mechanisms play a key role in regulat-
ing the expression of numerous cell-cycle proteins both in
the mitotic cell cycle and during meiotic progression in
oocytes (18–20). Translational regulation typically involves
the binding of specific RNA binding proteins (RBP) or mi-
croRNAs (miRNAs) to the untranslated regions of mR-
NAs. Multiple RNA binding proteins often act in a combi-
natorial manner and can promote or antagonise regulation
by miRNAs. Pumilio proteins are evolutionary conserved
members of the PUF (Pumilio and fem-3 binding factor)
RBP family and act together with other RBPs to repress
translation and/or promote mRNA degradation (21). PUF
family members contain a conserved RNA binding domain
comprising eight -helical repeats, that each recognise one
nucleotide of the consensus Pumilio binding element (PBE)
UGUANAUA (22–24). Pumilio proteins repress expression
of many cell-cycle regulatory proteins, including the CDK1
binding partner cyclin B in multiple organisms (21,25), and
a potential functional homologue of RGC-32, the atypical
CDK activator, RINGO, in Xenopus oocytes (26). Pumilio
proteins have been reported to repress translation or regu-
late message stability through several mechanisms that may
not be mutually exclusive. These include deadenylation of
poly(A) tails, decapping of the 5′ end of mRNAs and effects
on translation elongation (21).
We investigated the role of RGC-32 in the control of B
cell proliferation and usedEBV-infected cell lines as amodel
system to study the translational regulation of RGC-32 ex-
pression. We show that RGC-32 is required for the growth
and survival of EBV-immortalised cell-lines, indicative of
a key role in EBV-driven B cell transformation. We demon-
strate that the RGC-32 3′UTR is sufficient to direct transla-
tional repression of a reporter gene, in a manner dependent
on the presence of a PBE located adjacent to the poly(A)
signal. Loss of this PBE did not affect the site of mRNA
cleavage, but resulted in lengthening of the poly(A) tail. We
show that Pumilio 1 binds the RGC-32 3′UTR at lower
levels in EBV-infected cells where RGC-32 protein is ex-
pressed correlating Pumilio binding with RGC-32 transla-
tional repression in cells. We also show that knock-down
of Pumilio proteins in cells leads to increased expression of
endogenous RGC-32 protein and a corresponding increase
in polyA tail length. Our data therefore indicate that the
Pumilio-dependent RGC-32 translational repression mech-
anism involves shortening of poly(A) length. Interestingly,
in B cells where RGC-32 translation is repressed, mRNA
levels are both high and ribosome-associated indicating that
this Pumilio-dependent deadenylation mechanism does not




To create the inducible lentiviral RGC-32 shRNA vectors,
pairs of primers coding for shRNA 1 (Ind shRNA-R 2 and
Ind shRNA–F 2) and shRNA 2 (Ind shRNA-R 4 and Ind
shRNA –F 4) (Supplementary Table S1) were annealed and
inserted into the BglII and HindIII sites of pENTR-THT
III (gift from Dr H. Hochegger). Selected clones were in-
serted into pGLTR –x-GFP (gift from Dr H. Hochegger)
using the Gateway LR Clonase II enzyme kit (Invitrogen).
To generate the short RGC-32 3′UTR construct
(psicheck2 RGC32 3′UTR DSE) for luciferase assays,
the 3′UTR sequence (based on the NCBI NM 014059.2
cDNA clone) was amplified using the primers MW496
and MW497 (Supplementary Table S1) from cDNA pre-
pared from Mutu I cells. The PCR product was digested
and inserted into the XhoI and NotI sites of psicheck2
(Promega). psicheck2 RGC32 3′UTR DSE (containing
sequences including the downstream sequence element
(DSE)) was generated by amplifying the 3′UTR sequence
of RGC-32 in addition to a further 500 bp downstream
region from the bacmid RP11–769F14 (Bacpac resources)
using the primers MW496 and MW1506 (Supplementary
Table S1). The PCR product was digested and inserted
into the XhoI and NotI sites of psicheck2. psicheck2
3′UTR-GAPDH was generated by inserting the 3′UTR
sequence of GAPDH (synthesized using GeneArt Strings,
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Invitrogen) into the XhoI and NotI sites of psicheck2.
To create psicheck2 RGC-32 ORF (open reading frame)
the RGC-32 coding sequence was amplified from cDNA
using the primers MW524 and MW525 (Supplementary
Table S1). The PCR product was digested and inserted into
the XhoI and NotI sites of psicheck2. To create pRTS-1
RGC-32, the RGC-32 open reading frame was amplified
by PCR from pFLAG RGC-32 (15) using primers MW592
and MW593 (Supplementary Table S1) to introduce SfiI
sites. The PCR product was then cloned into the SfiI sites
of pUC19 SfiI (gift from Prof. G. Bornkamm). An SfiI
fragment containing the RGC-32 ORF was then excised
and cloned into the SfiI sites of pRTS-1 (gift from Prof G.
Bornkamm) replacing the luciferase gene (27).
Site-directed mutagenesis and deletion
The Q5® Site Directed Mutagenesis Kit (New England
Biolabs) was used to generate the 3′UTR mutants and
deletions according to the manufacturer’s instructions. All
primers were designed using NEBaseChanger™ software
(Supplementary Table S1).
Cell lines and culture
EBV infection of CD19 positive primary B cells was carried
out as described previously (28). Cell lines were maintained
as described previously (29) and passaged twice weekly.
DG75 is an EBV negative Burkitt’s lymphoma cell line (30).
Akata (31), Elijah (32) and Mutu I (33) are EBV-positive
latency I Burkitt’s lymphoma cell lines. Mutu III is a cell
line clone derived from Mutu I cells that drifted to a la-
tency III gene expression profile in culture (33). IB4 (31)
andGM12878 (obtained fromCoriell Cell Repositories) are
EBV-immortalised lymphoblastoid cell lines (latency III)
generated by infection of resting B cells in vitro. To create
IB4 stable cell lines, cells were diluted 1:3 one day prior to
transfection and 5× 106 cells were washed and resuspended
in 100 l of Buffer T (Neon Transfection Kit, Invitrogen). 5
g of pRTS-1 or pRTS-1 RGC-32 was added to the cells to
a final volume of 120 l. Cells were transfected using a 100
l Neon tip at 1300 V, 30 ms and 1 pulse. Transfected cells
were then transferred to a flask containing pre-warmed me-
dia (without antibiotics). After 48 h 100 g/ml hygromycin
B (Invitrogen) was added to select for transfected cells. The
hygromycin B concentration was increased to 300g/ml af-
ter 1 week. Stable hygromycin-resistant cell lines were estab-
lished within 4 weeks of selection that inducibly expressed
GFP in the absence (IB4 pRTS-1) or presence of RGC-
32 (IB4 pRTS-1 RGC-32).For protein stability experiments,
Mutu I and Mutu III cells were diluted to 5 × 105 cells/ml
24 h prior to treatment with 50 or 100 g/ml cycloheximide
(Sigma) or 50 M MG132 (Sigma). Cells were incubated
with inhibitors for up to 24 h and analysed by western blot-
ting.
Polysome gradient analysis
Where indicated, 250 g/ml of puromycin was added to 5
× 107 cells for 15 min at 37◦C followed by 100 g/ml of
cycloheximide for a further 3 min. Alternatively, 100 g of
Harringtonine or the equivalent volume of DMSO (0.1%)
was added for 3 mins before the addition of cycloheximide.
Polysomes were purified and analysed as described previ-
ously (15).
Transient transfections and luciferase assays
For B cell 3′UTR reporter assays, 107 DG75 cells were ini-
tially transfected with 0.1–2 g of plasmid using a Gene
Pulser II (Biorad) at 230 V, 950F. 1g of reporter plasmid
was used for all subsequent experiments. For miRNA ex-
periments, 2 × 104 HeLa cells were plated in a 96-well plate
24 h prior to transfection with 100 ng of psicheck2 RGC32
3′UTR DSE or psicheck2 RGC-32 ORF in combination
with 100 nM of miR-30c, miR-30d or a mutant miR-30c
(Invitrogen) using Dharmafect Duo transfection reagent
(Dharmacon, GE Healthcare). Cells were harvested after
48 h. For 3′UTR reporter assays in U2OS cells, cells were
seeded in 24-well plates at a density of 5 × 104 cells/well
24 h prior to transfection. Cells were transfected with 100
or 200 ng of plasmid using Dharmafect Duo transfection
reagent and cells were harvested 48 h after transfection. Lu-
ciferase assays were carried out as described previously (29),
but the activity of the Renilla luciferase reporter gene was
adjusted for transfection efficiency by dividing by the ac-
tivity of the constitutively expressed firefly luciferase gene,
carried on the same psicheck2 plasmid.
Constitutive RGC-32 silencing
Constitutive silencing of RGC-32 was performed
using MISSION lentiviral transduction particles
(Sigma) containing shRNA sequences against human
RGC-32 (shRNA 3: TRCN0000150738, shRNA 4:
TRCN0000151271, shRNA 5: TRCN0000153026, shRNA
6: TRCN0000156253, shRNA 7:TRCN0000157549) in the
TRC1.5 lentivector backbone. MISSION pLKO.1-puro-
CMV-TurboGFP™ positive control transduction particles
were used as a control. 5 × 104 GM12878 or IB4 cells were
transfected by spinoculation for 2 h at 1200g at 32◦C at
either MOI 1 or MOI 5. Transfected cells were selected
by addition of 0.5 g/ml of Puromycin (Sigma) after 3
days and selection was carried out for time periods up
to 5 weeks. The number of live cells was determined by
counting cells that excluded trypan blue stain (Sigma).
For rescue experiments, IB4 pRTS-1 and IB4 pRTS-1
RGC-32 cell lines were treated with 1 g/ml doxycycline
(Sigma) for 24 hrs to induce the expression of GFP in the
absence or presence of RGC-32. 1 × 105 cells were then
transduced with a mix of shRNA 5 and shRNA 6 MIS-
SION lentiviral transduction particles orMISSION lentivi-
ral non-mammalian shRNA control transduction particles
(SHC002V) at a MOI of 5 as described above. After trans-
duction cells were maintained in 1 g/ml doxycycline and
300g/ml hygromycin B for 4 days followed by the selection
of transfected cells for up to 5 days by the addition of 0.5
g/ml of puromycin (Sigma). Cells were harvested at differ-
ent time points, washed once in phosphate buffered saline
(PBS) and fixed in 0.5% formaldehyde (Sigma). Fixed cells
were stored at 4◦C until analysed by flow cytometry (BD
Accuri) to determine the number of GFP positive cells.
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Inducible RGC-32 silencing and cell sorting
Lentiviral particles were generated using the GLTR sys-
tem (34) by transfecting HEK-293 FT cells (gift from Dr
H. Hochegger) with pLK01 scrambled shRNA (gift from
Dr H. Hochegger), pLK01 shRNA RGC32.1, or pLK01
shRNA RGC32.2 and packaging vectors pVSV-G and
psPAX 2 (gift from Dr H. Hochegger) using Fugene HD
(Promega) in 10 cm dishes. Lentiviruses were harvested by
pelleting cells, decanting the culture supernatant and filter-
ing it through a 0.45 m MillexGP filter (Millipore). The
cleared supernatants were aliquoted and 1 ml of lentivirus
was added to 5 × 106 GM12878 or IB4 cells. Cells were as-
sayed for the constitutive expression of GFP after 5 days
by flow cytometry using a BD FACS Canto or BD Accuri
C6 (BD Biosciences). shRNA expression was induced by
addition of doxycycline at 0.5 g/ml to 2 × 105 cells in a
24-well plate. Cells were split after 5 days and then every
2 days. Cells were harvested at different time periods af-
ter shRNA induction and the number of GFP positive cells
determined by flow cytometry as described above. Sorting
of GFP-positive cells was performed using a BDFACSAria
(BD Biosciences).
Pumilio silencing
Pumilio silencing was performed using the ON-TARGET
plus siRNA against Pumilio 1 (Dharmacon, GE Health-
care L-014179-00-0005) and Pumilio 2 (Dharmacon, GE
Healthcare L-014031-02-0005) using the Neon transfection
system (Thermofisher), according to the manufacturer’s in-
structions. Briefly, 5× 106 cells were transfected with a final
concentration of 200 nM or 500 nM of a 1:1 mix of siRNA
against Pumilio 1 and 2 or a non-target control using 100
l tips and electroporated with 1 pulse at 1300 V for 30 ms.
GM12878 cells were incubated in antibiotic-freeRPMI sup-
plemented with 10% FCS and 1× Glutamax (Gibco) for
2 days before harvesting. Elijah cells were transfected, in-
cubated for 24 h and then re-transfected with siRNAs and
harvested after a further 24 h.
RNA extraction
For cell panel analysis, total RNA was extracted using
TriReagent (Sigma) and RNA samples then purified using
the RNeasy kit (Qiagen). For extraction of reporter mRNA
from luciferase reporter transfections, total RNA was ex-
tracted using TriReagent and DNA digested using 10 units
of DNase I (Roche) for 15 min at 37◦C before quenching by
addition of 5mM EDTA. Samples were purified by extrac-
tion with acidic phenol–chloroform (Ambion) and RNA
then purified using the RNeasy kit.
RT-QPCR
RNA concentrations were determined using a Nanodrop
2000 (Thermo Scientific) and 1 g was used to prepare
cDNA using the ImProm II reverse transcription kit with
random primers (Promega). Quantitative PCR was per-
formed in duplicate using the standard curve absolute quan-
tification method on an Applied Biosystems 7500 real-time
PCR machine as described previously (35) using primers
for RGC-32 (exon 3 MW86 and MW87 or exon 4–5
MW387 and MW388 (15)), GAPDH (MW84 and MW85)
(15)), actin (MW417 and MW418 (15)) 2 microglobulin
(MW1447 and MW1448), CD21 (MW1132 and MW1133)
and cyclin B (MW1362 and MW1363 (Supplementary Ta-
ble S1). The efficiency of all primers was determined prior
to use and in each experiment and all had amplification ef-
ficiencies within the recommended range (90–105%).
3′ RACE
Total RNA (0.5g) wasmixed with 1l of 20M3′ RACE
primer mix (36) and denaturation carried out at 70◦C for
5 min. Samples were then incubated on ice for 5 min be-
fore the addition of 15 l of reverse transcription ImpromII
reaction mix (Promega) and incubation at 25◦C for 5 min
and 42◦C for 1 h. cDNA was precipitated by ethanol pre-
cipitation in 300 mM NaCl and 1 g of Glycogen (Roche)
overnight at –20◦C and pelleted at 13 000 rpm in a Heraeus
benchtop microfuge for 30 min at 4◦C. Pellets were washed
twice in ice-cold 70% ethanol and resuspended in 20 l of
DNase-free water. Nested PCR was performed with RGC-
32 specific primers in exon 3 (MW86 (15)) in the first PCR
and at the 3′ end of the ORF in exon 4 (MW387 (15)) in
the second PCR. This would give a PCR product of the
3′UTR plus 43 nucleotides. For 3′RACE on luciferase mR-
NAs, three sequential nested PCR reactions were carried
out. The first PCR used a primer specific to the 5′end of the
Renilla luciferase ORF (MW1422), the second PCR used
a primer specific to the 3′ end of the ORF (MW1446) and
the third PCR used a primer specific to the 3′ end of the
RGC-32 3′UTR (MW1482). PCR products were purified
using the Qiaquick PCR purification kit (Qiagen), analysed
by agarose gel electrophoresis and sequenced (Eurofins ge-
nomics).
RNA immunoprecipitation experiments
Cells were harvested and passed through a 70 m filter to
obtain a single cell preparation in PBS. 1 × 107 cells were
then fixed in 1% formaldehyde for 10 min at room tem-
perature to crosslink protein and RNA. The reaction was
quenched with 0.125 M glycine for 5 min, and cells col-
lected by centrifugation at 1500 rpm for 10 min at 4◦C.
Cells were washed with ice cold PBS, and frozen at –80◦C
until required. Cell pellets were lysed on ice for 30 min in
250 l lysis buffer per 107 cells, supplemented with protease
inhibitors (Roche) and RnaseOUT (Invitrogen) (50 mM
Hepes pH 7.4, 1% NP40, 0.25% NaDOC, 1 mM EDTA,
2 mM DTT, 150 mM NaCl, 5 mM MgCl2). Sonication for
5 s at 25% amplitude was then performed on ice. Cell de-
bris was pelleted and discarded and the lysate was diluted
to 0.5 mg/ml in IP dilution buffer supplemented with pro-
tease inhibitors and RnaseOUT (50 mM Hepes pH 7.4, 1
mM EDTA, 2 mM DTT, 150 mM NaCl, 5 mMMgCl2). A
100 l aliquot of lysate was then retained as an input con-
trol at this stage.
Pre-blocked protein G sepharose beads for use in im-
munoprecipitations were prepared by incubating 500 l of
a 50% protein G Sepharose (Sigma) slurry with incubation
buffer supplemented with BSA 0.5% and yeast tRNA 100
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Figure 1. Analysis ofRGC-32 expression onEBV infection of naı¨ve B cells.
CD19 positive B cells (UI) were infected and samples taken for protein
and RNA analysis up to 21 days post-infection. (A) Western blot anal-
ysis of RGC-32 protein expression and the expression of representative
EBV latent proteins (EBNA 2 and EBNA 3A). Ponceau S staining of the
membrane was used as a loading control. (B) Q-PCR analysis of RGC-
32 mRNA levels normalised to levels of 2 microglobulin mRNA and ex-
pressed as fold change from uninfected cells. Data show themean +/- stan-
dard deviation of duplicate PCR samples and are representative of two in-
dependent experiments. (C) Q-PCR analysis of CD21 (CR2) expression as
in (B).
g/ml (Fisher) (50 mM Hepes pH 7.4, 0.2% NP40, 0.05%
NaDOC, 1 mM EDTA, 2 mMDTT, 150 mMNaCl, 5 mM
MgCl2, protease inhibitors) for 30 min at 4◦C with rota-
tion. A 45l aliquot of 50% proteinG Sepharose slurry was
diluted in 250 l of incubation buffer supplemented with
BSA 0.5%, and yeast tRNA (100 g/ml). Following a 10
minute equilibration at room temperature, the beads were
incubated overnight with 10 g of antibody at 4◦C with ro-
tation (Goat Anti-Pumilio 1 (Bethyl Labs A 300-201 A) and
Goat IgG Isotype Control (Fisher 10087232).
Antibody bound beads were washed three times with 500
l incubation buffer supplemented with RnaseOUT. Next,
the beads were incubated overnight with 0.5 mg of cell ex-
tract (1 ml) at 4◦C, with rotation. Complexes were then
washed three times in IP dilution buffer, with a final resus-
pension in 500 l. 100 l of the complexes were retained
for western blot analysis, whilst the remainder were resus-
pended in 500 l of reverse buffer (50 mM Tris–HCl pH 7,
5 mM EDTA, 10 mM DTT, 1% SDS, RnaseOUT). At this
stage, the 100 l input control aliquots were also diluted
with 100 l reverse buffer. The immunoprecipitations and
inputs were incubated for 1 h at 70◦C, to reverse cross links.
5 l of Proteinase K (10 mg/ml) was added and the sample
incubated for 30 min at 50◦C. RNA was purified by the ad-
dition of 500l acidic phenol:chloroformpH4.5 (Ambion).
RNA was further purified over an RNAeasy column (Qia-
gen), according to the manufacturer’s guidelines, and eluted
in 30 l H2O. The ImProm-II Reverse Transcription Sys-
tem (Promega) was used to generate cDNA from 4 l of in-
put and each immunoprecipitated sample, ready for QPCR
analysis withRGC-32 (exon 4–5MW387 andMW388 (15)),
cyclin B (MW1362 and MW1363) (Supplementary Table
S1) andGAPDH (MW84 andMW85 (15)) specific primers.
Percentage input signals for cyclin B and RGC-32 for each
Pumilio 1 immunopreciptationwere determined from an in-
put standard curve from each cell line. These signals were
then divided by the percentage input signal obtained in the
IgG control immunoprecipitation to determine the fold en-
richment and then normalised to the background fold en-
richment for a non target mRNA (GAPDH).
Extension poly(A) test (ePAT) assay
PolyA tail length assays were carried essentially as described
in (37) using the primers shown in Supplementary Table S1.
Briefly, 1 g of total RNA was mixed with 1 l of 100 M
anchor primer and samples denatured at 80◦C for 5 min
before being left to cool to room temperature. Klenow la-
belling reactions were performed in a final volume of 20 l
using the Superscript III kit (Invitrogen), 5 units of Klenow
enzyme and 1 l of RNaseOUT (Invitrogen) at 25◦C for
1 h. Klenow was denaturated at 80◦C for 10 min and the
reactions placed at 55◦C for 2 min before addition of 1 l
of Superscript Revertase III (Invitrogen). The reverse tran-
scription reaction was carried for 1 h at 55◦C before denat-
uration of the enzyme at 80◦C for 10 min. cDNA was puri-
fied by ethanol precipitation overnight at –20◦C in 300 mM
NaCl with 1 g of glycogen (Roche). cDNA was pelleted at
13 000 rpm for 30 min at 4◦C followed by two washes with
ice-cold 70% ethanol. The pellets were air dried and resus-
pended in 20 l of DNase free water. Nested PCRs were
performed for RGC-32 mRNA using the reverse univer-
sal primer MW1538 and primer MW387 in the first round
and primer MW1602 in the second round. Nested PCR for
GAPDH used the reverse universal primer MW1538 with
primer MW1453 in the first round andMW1562 in the sec-
ond round. For the ePAT assay on luciferasemRNA, nested
PCRs were carried out using the reverse universal primer
MW1538 and primers in the luciferase ORF (first round;
MW1422 and second round; MW1446). A third PCR spe-
cific for the RGC-32 3′UTR was then carried out using the
universal primer and primer MW1602. A0 control PCR
products (the 3′UTRwith no polyA tail) were amplified us-
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ing MW1602 and MW1705 for RGC-32 and MW1562 and
MW1563 for GAPDH. PCR products were analysed on a
2% agarose gel.
Immunoblotting
Exponentially growing cells were pelleted, washed twice in
cold PBS and lysed in 1× Gel sample buffer (50 mM Tris–
HCl pH 6.8, 4% SDS, 10% glycerol, 1 mM EDTA, 0.01%
Bromophenol Blue and 5% -Mercaptoethanol, minus or
plus 300 mMNaCl). SDS-PAGE and immunoblotting were
carried out as described previously (29,38). The following
antibodies were used for immunoblotting: anti-actin 1:5000
(A-2066, Sigma), anti-RGC-32 as described in (15), anti-
Pumilio 1 at 1:5000 (A300-201A, Bethyl Laboratories, Inc.),
anti-Pumilio 2 at 1:2000 (A300-202A, Bethyl Laboratories,
Inc.), anti-EBNA2 (PE2) at 1:200, anti-EBNA3A (exalpha)
at 1:1000, anti-LMP1 (CS1–4) at 1/300, anti-MYC (9E10
culture supernatant) at 1/15. HRP conjugated anti-rabbit
and anti-mouse secondary antibodies (Cell Signalling) were
used at 1:2000 and HRP conjugated anti-goat secondary
antibodies at 1:5000 (DAKO A/S, Denmark). Western blot
quantification was carried out using Li-COR Image studio
software using images captured using the Li-COR Odyssey
Imaging system. Signals were adjusted for background and
normalised to the signal for actin.
RESULTS
RGC-32 protein expression is induced on EBV infection of
primary B cells
We previously showed that RGC-32 protein is expressed
in EBV-positive B cell lines displaying the full panel of vi-
ral gene expression (latency III), but not in EBV-negative
cell lines or EBV-infected cell lines with the more restricted
latency I gene expression pattern (15). Since we had also
observed that infection of EBV-negative BL cell lines by
EBV induced RGC-32 protein expression (15), we exam-
ined whether RGC-32 expression was induced in the more
physiological setting of EBV infection of naı¨ve resting B
cells. Infection of resting B cells leads to the generation of
immortalised lymphoblastoid cell lines displaying the la-
tency III pattern of viral gene expression. We found that
RGC-32 protein was expressed at very low levels in rest-
ing B cells, but was upregulated on EBV infection (Figure
1A), consistent with our previous observations in BL cells
(15). Western blotting confirmed that EBV latency III as-
sociated proteins were expressed at the expected times post-
infection, with EBNA 2 expression detectable early (from
day 1) and EBNA 3A expression detectable slightly later
(from day 2) (39) (Figure 1A). Interestingly, RGC-32 pro-
tein expression began to increase 3 days post-infection co-
inciding with the point at which EBV-infected cells begin to
proliferate rapidly (40).
We previously observed that RGC-32 mRNA expression
was very low in EBV-infected latency III cells although
RGC-32 protein was expressed (15). This contrasted with
the high RGC-32 mRNA levels detectable in cell lines that
did not express RGC-32 protein (as a result of a transla-
tional block) (15). We found the same inverse relationship
between RGC-32 mRNA and protein expression on EBV
infection of naı¨ve B cells. RGC-32 mRNA expression de-
creased rapidly by day 1 post-infection and remained low
(Figure 1B). As a control we examined mRNA expression
of the EBNA2 activated target gene CD21 (CR2) (41) and
found that CD21 mRNA levels were increased as expected
from day 1 post-infection (Figure 1C).
These results therefore confirmour previous observations
in established cell lines, that EBV infection induces RGC-32
protein expression. They also confirm our observations that
RGC-32 mRNA and protein levels do not correlate with
one another, with RGC-32 protein expression detected in
cells with very low levels ofmRNA. In fact, given thatRGC-
32mRNA levels decrease by day 1 post-infection andRGC-
32 protein expression increases 3 days post-infection, they
point to RGC-32 control through distinct transcriptional
and post-transcriptional mechanisms.
RGC-32 expression is required for the survival of EBV im-
mortalised B cells
To determine whether the expression of RGC-32 was re-
quired for the growth of EBV-immortalised LCLs, we
sought to silence RGC-32 expression in EBV-infected LCLs
using an RNA interference approach. Since B cell lines are
difficult to transfect with plasmids at high efficiency, we
used lentiviruses to express RGC-32 targeting shRNAs. Ini-
tially, we transduced an EBV-immortalised cell line with
puromycin-selectable lentiviruses (Sigma) designed to con-
stitutively express 5 different shRNAs (shRNAs 3 to 7).
At a multiplicity of infection (MOI) of 1, after 3 weeks
of selection we observed decreases in the expression level
of RGC-32 protein by up to 78% with different shRNAs
(Figure 2A). However, this reduction in RGC-32 protein
expression was not sustained in selected cells. When cells
were selected for 5 weeks, those transduced with shRNA-
expressing lentiviruses displayed levels of RGC-32 protein
expression higher than those in untransduced cells for all
shRNAs other than shRNA 6 (85% of control) (Figure 2A).
In these experiments we used a control lentivirus express-
ingGFP, since the non-targeting control shRNA-expressing
lentivirus initially supplied by the manufacturer displayed
high levels of non-specific toxicity in all cell lines tested and
no alternative was available at that time. The loss of RGC-
32 knock-down in these longer-term selected cell popula-
tions could indicate the loss of cells with reduced RGC-32
expression from the cultures due to cell death. Consistent
with this possibility, our initial analysis after four days of
drug selection found that the number of shRNA transduced
cells remaining was 52%, 67% and 77% of the eGFP control
cells for shRNAs 5, 6 and 3 respectively. To explore this fur-
ther, we used combinations of RGC-32 targeting shRNA
expressing lentiviruses and increased the MOI to achieve
higher transduction efficiencies.
We observed that following the transduction of cells at a
MOI of 5 with RGC-32 targeting lentiviruses, the number
of live cells in the culture decreased rapidly during selection
for up to 8 days, with increased cell death observed when
increasing numbers of RGC-32 targeting lentiviruses were
combined (Figure 2B). These data therefore indicate that si-
lencing of RGC-32 leads to the death of EBV-immortalised
cells. To confirm that these effects were due to the deple-
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Figure 2. Depletion of RGC-32 mRNA using lentiviruses constitutively expressing shRNAs. (A) Western blot analysis of RGC-32 protein expression in
GM12878 cells in untransduced cells (Unt) or in transduced cells after 3 or 5 weeks of selection in puromycin. Actin was used as a loading control. Cells
were transduced at a MOI of 1 with Mission (Sigma) lentiviral particles carrying shRNAs targeting RGC-32 (shRNA 3 to 7) or the GFP coding sequence
(eGFP) as a control. Numbers under the panels show quantification of RGC-32 western blot signals normalised to actin and expressed relative to the
untransduced control. (B) Numbers of live cells determined by trypan blue exclusion and cell counting at the indicated times following transduction of IB4
cells with Mission lentiviral particles at a MOI of 5 and selection of the transduced cells using puromycin. Data show the mean of four independent cell
counts ± standard deviation and are expressed relative to the numbers of live cells at day 0. (C) Analysis of the proportion of GFP positive cells present
in cultures of IB4 cells stably expressing a control doxycycline inducible GFP expressing plasmid (pRTS-1) following lentiviral transduction and during
puromycin selection. Cells were cultured in doxycycline for 24 h prior to transduction with either non-targeting shRNA expressing lentiviruses or a mix of
RGC-32 targeting lentiviruses (shRNA 5+6) at an MOI of 5. Untransduced cells and untransduced cells cultured in the presence of puromycin were used
as controls. The number of GFP positive cells in lentivirus transduced cells was expressed relative to the number of GFP positive cells in untransduced
samples at each time point. (D) The proportion of GFP positive cells present in cultures of IB4 cells stably expressing a doxycyclin inducible GFP and
RGC-32 expressing plasmid (pRTS-1 RGC-32) following lentiviral transduction and during puromycin selection.
tion of RGC-32 and not the result of non-specific toxicity,
we performed a rescue experiment by generating an EBV-
immortalised cell line that could be induced to overexpress
RGC-32 mRNA and thus squelch the effects of RGC-32
targeting shRNAs. We were not able to express a ‘resistant’
form of RGC-32 mRNA as the two most efficient RGC-
32 shRNAs (shRNA 5 and 6) target different regions of
the RGC-32 open reading frame. Cells were stably trans-
fected with a plasmid containing a doxycycline-inducible
bidirectional promoter that drives GFP expression in one
direction and RGC-32 expression in the other direction
(pRTS-1 RGC-32) (Supplementary Figure S1) (27). A con-
trol cell line was also generated using the control pRTS-1
plasmid that drives inducible GFP expression in one direc-
tion and firefly luciferase expression in the other direction
(pRTS-1) (Supplementary Figure S1). We treated both cell
lines with doxycycline for 24 h to induce GFP expression
in the absence or presence of RGC-32 expression and then
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transduced cells with lentiviruses expressing non-targeting
(newly supplied by the manufacturer) or RGC-32 target-
ing shRNAs. We then determined the numbers of surviv-
ing GFP positive cells by flow cytometry during positive se-
lection of transduced cells using puromycin and compared
this to untransduced cells (Figure 2C and D). Consistent
with our previous results (Figure 1B), we found that in the
pRTS-1 control cell line expressing endogenous RGC-32
there was a large reduction in the numbers of GFP posi-
tive cells present in cultures transduced with RGC-32 tar-
geting shRNAs during selection (Figure 2C). In contrast,
GFP positive cell numbers were maintained at high lev-
els in cells transduced with non-targeting lentiviruses (Fig-
ure 2C). However, cells co-expressing GFP and exogenous
RGC-32 (pRTS-1 RGC-32) transduced with RGC-32 tar-
geting lentiviruses survived much better during selection
(Figure 2D). In cells where exogenous RGC-32 expression
was induced the proportion of GFP positive cells was 50%
of those in untransduced cells after 5 days of selection with
RGC-32 targeting shRNAs, compared to 6% in the control
cell line (Figure 2C and D). Exogenous expression of RGC-
32 therefore protects cells from cell death induced by RGC-
32 targeting shRNAs indicating that the effects of these
shRNAs are specific.
To provide further confirmation of these results, we
also created lentiviruses that express doxycycline-inducible
shRNAs and constitutively express GFP. We could then
monitor cell survival again by determining GFP positive
cell numbers at times after shRNA induction. Again, flow
cytometry detected a decline in the numbers of GFP-
positive cells in the cultures of two EBV-immortalised
LCLs (GM12878 and IB4) following doxycycline treatment
of cells transduced with lentiviruses expressing shRNAs
against RGC-32 (1, 2 and 3) (Figure 3A and B). In con-
trast, induced expression of a control scrambled shRNA
had no effect on the percentage of GFP-positive cells (Fig-
ure 3A and B). After enrichment of transduced GM12878
cultures for GFP-positive cells by cell sorting, we confirmed
that RGC-32 protein expression was successfully downreg-
ulated in cells expressingRGC-32-targeting shRNAs.RGC-
32 protein expression was reduced to 26% and 4.5% of con-
trol levels following the induction of RGC-32 shRNA 1 and
2, respectively (Figure 3C). Taken together, the results of
our depletion experiments demonstrate that RGC-32 ex-
pression is required for the survival of EBV-immortalised
LCLs.
RGC-32 mRNA is associated with active ribosomes
We previously demonstrated that despite a lack of RGC-
32 protein expression in EBV-infected latency I cells, RGC-
32 mRNA was still found within the polyribosome frac-
tion (polysomes) of cytoplasmic mRNA complexes isolated
by sucrose gradient centrifugation (15). Since we confirmed
that RGC-32 regulation on primary EBV infection mir-
rors the regulation of RGC-32 detected in latency I and
latency III EBV-infected cell lines, we continued our stud-
ies into the post-transcriptional regulation of RGC-32 ex-
pression, using these cell lines as a model system. Our ini-
tial experiments addressed whether the polysomal fractions
with which RGC-32 mRNA was associated in latency I
Figure 3. Depletion of RGC-32 mRNA using lentiviruses inducibly ex-
pressing shRNAs. (A) Flow cytometry analysis of the numbers of GFP-
positive GM12878 cells in a time course following doxycycline-induced ex-
pression of RGC-32 targeting shRNAs (shRNA 1–3) or a control scram-
bled shRNA in cells transduced with lentiviruses that also constitutively
express GFP. Data show the mean of two biological replicates ± standard
deviation and are expressed relative to the number of GFP positive cells
following transduction but prior to doxycycline shRNA induction (day 0).
(B) Analysis of the numbers of GFP-positive IB4 cells following induc-
tion of shRNA expression as in (A). (C) Western blot analysis of RGC-32
and actin protein levels 4 days after doxycycline induction. GM12878 cells
were transduced with scrambled or RGC-32 targeting shRNAs (shRNA
1 or 2) and sorted to enrich the GFP positive population by flow cytom-
etry. Numbers show quantification of RGC-32 western blot signals from
GFP positive sorted cells normalised to actin and expressed relative to the
scrambled control.
cells lacking RGC-32 protein expression, represented active
polysomes. We therefore treated latency I and latency III
cells with the translation elongation inhibitor, puromycin,
which causes premature peptide chain termination and ri-
bosome dissociation. We found that RGC-32 mRNA and a
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Figure 4. Analysis of the RGC-32 3′UTR. (A) 3′RACE analysis of RGC-
32 total or cytoplasmic mRNA from a panel of EBV negative and EBV-
positive latency I (I) or latency III (III) B cell lines. (B) Luciferase reporter
assays carried out using constructs containing the RGC-32 3′UTR cloned
downstream of the Renilla luciferase gene in the psicheck2 vector. The 3′
RGC-32 gene sequence cloned into the reporter lacks the U-rich and GU-
rich downstream sequence element (DSE) present in the endogenousRGC-
32 gene, so the synthetic PAS in the psicheck2 vector drives polyadenyla-
tion and cleavage. 1 or 2 g of the construct was transfected into the EBV-
negative DG75 BL cell line and luciferase assays carried out after 48 h.
Data show Renilla luciferase signals normalised to the internal Firefly lu-
ciferase control and are expressed relative to the psicheck2 empty vector
Renilla luciferase signal. The mean of two biological replicates ± standard
deviation is shown. Student’s t-test for the 3’UTR containing reporter con-
struct compared to the empty vector control show P < 0.001 (**) and P
< 0.05 (*). (C) RNA sequence of the 386 nucleotide 3′UTR of RGC-32
mRNA derived from sequencing of the 3′RACE assay products. Putative
AU-rich elements (blue), Pumilio binding elements (red) and a cytoplas-
mic polyadenylation element (yellow) are shown. The endogenous PAS is
boxed in red.
control mRNA (GAPDH) were no longer associated with
large polysomes in either cell type following puromycin
treatment (Supplementary Figure S2). This is consistent
with the presence of active ribosomes associated with RGC-
32 mRNA in both latency I and latency III cells. We con-
firmed these results using the translation inhibitor, har-
ringtonine. Harringtonine blocks the transition from initi-
ation to elongation but does not inhibit initiation or ongo-
ing elongation (polysome run-off). During brief harringto-
nine treatment, elongating polysomes will therefore com-
plete translation and newly initiating ribosomes will stall
near the translation start site. We found that harringtonine
treatment led to the loss of polyribosome associated RGC-
32 mRNA in both latency I and latency III cells (Supple-
mentary Figure S3). These data indicate that even in latency
I cells, RGC-32 mRNA associates with ribosomes that are
capable of completing elongation.
We had previously been unable to detect any RGC-32
protein expression in cell lysates from EBV negative and la-
tency I cell lines using standard whole cell lysate prepara-
tion techniques. The detection of actively elongating RGC-
32 mRNA polysomes in latency I cells however, prompted
us to re-address whether we could detect even low levels of
RGC-32 protein in these cell lines using alternative protein
solubilisation techniques. We found that in the presence of
high salt, RGC-32 protein was detectable at low levels in
latency I cells and at even higher levels in latency III cells
(Supplementary Figure S4). These data therefore indicate
that some RGC-32 protein is produced in latency I cells, but
that levels are very low and inconsistent with the high level
of mRNA.
We next explored the possibility that RGC-32 protein
is produced in latency I cells but is either unstable or ac-
tively degraded. We had previously treated latency I cells
with the proteasome inhibitor MG132 and found that this
did not lead to the appearance of detectable RGC-32 pro-
tein expression. This indicates that proteasome-mediated
degradation is not responsible for the discrepancy between
mRNA and protein expression (15). We repeated this ex-
periment using our improved solubilisation technique and
again found that MG132 treatment did lead to an in-
crease in RGC-32 protein expression (Supplementary Fig-
ure S5C). We also examined the half-life of the RGC-32
protein in both latency III and latency I cell lines by block-
ing protein synthesis using cycloheximide and monitoring
RGC-32 protein levels over time. We found that RGC-32
was stable up to 24 h after cycloheximide treatment inMutu
III latency III cells (Figure S5A). In parallel, we determined
the stability of two short half-life proteins, myc and the EBV
latent membrane protein 1 (LMP1). Levels of both proteins
reduced as expected over the course of the experiments with
half-lives of 2.5 and 8 h respectively, similar to published re-
ports (42,43). Latency I cells are more susceptible to apop-
tosis than latency III cells, since the expression of latency III
associated EBV proteins provides protection from apopto-
sis. It was therefore only possible to treat latency I cells for
up to 8 h with the concentrations of cycloheximide required
to block protein synthesis. However, we observed no loss
of RGC-32 protein over this period (Supplementary Figure
S5B). A reduction in RGC-32 protein stability or proteaso-
mal degradation does not therefore appear to be responsible
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Figure 5. The role of Pumilio binding elements in 3′UTR-mediated repres-
sion. (A) Diagram showing the Renilla luciferase reporter constructs gen-
erated by site-directed mutagenesis of the wild-type RGC-32 3′UTR con-
struct. Each of the four putative PBEs was mutated to generate mPBE1–
4. (B) Luciferase reporter assays carried out by transfecting 1 g of each
construct into DG75 cells. Results show the mean ± standard deviation of
four independent experiments normalised as in Figure 4. Student’s t-test
for mutants compared to the wild-type 3′UTR show P < 0.001 (**) and
P < 0.05 (*).
for the low levels ofRGC-32 protein in EBV infected latency
I cells.
The RGC-32 3′ untranslated region represses translation
Since our data thus far were consistent with translational
control of RGC-32 expression in EBV infected cells, we
investigated the potential roles of RGC-32 mRNA un-
translated regions (UTR) in regulating RGC-32 expression.
RGC-32 mRNA has 5′ and 3′UTRs of approximately 300
and 400 nts, respectively. However, since polysome gradi-
ent analysis indicated that there was not a block to RGC-
32 translation initiation in latency I cells and 5′UTR di-
rected effects on translation normally affect initiation, we
focused our analysis on the RGC-32 3′UTR. Cis-acting se-
quences in mRNA 3′UTRs have been previously shown to
have the ability to direct translational repression at post-
initiation steps, where it appears that RGC-32 translation is
controlled in latency I cells.We first examined whether there
were any differences in 3′UTR length between EBV nega-
tive, latency I or latency III cells that could be responsible
for differential RGC-32 translation. 3′RACE experiments
detected a single RGC-32 3′UTR product of identical size
in both total and cytoplasmic RNA samples in all cell lines
tested corresponding to a 3′UTR length of 386 nts (Figure
4A andC). This is 9 nts shorter than the 3′UTR recorded for
the isoform of RGC-32 (AF036549) (14) that we previously
demonstrated was the only RGC-32 isoform expressed in
B cell lines (15). Sequence analysis of the 3′RACE products
found no nucleotide sequence differences and confirmed the
use of the same polyadenylation signal and the presence of
the same cleavage site across cell lines (data not shown).
We next investigated whether the 3′UTR of RGC-32
could direct translational repression. We cloned the RGC-
32 3′UTR downstream of a Renilla luciferase reporter gene
and transiently transfected this construct into the EBV-
negative cell line, DG75. As a control, we also cloned
the similar length sequence of the RGC-32 open reading
frame (ORF) downstream of the luciferase gene. In these
constructs, polyadenylation and cleavage were directed by
the synthetic polyadenylation signal present in the reporter
construct, since we did not include the downstream se-
quence element (DSE) required for usage of the endogenous
polyadenylation signal in the RGC-32 3′UTR (Figure 4B).
Our results demonstrated that the presence of the RGC-32
3′UTR resulted in a 40–46% decrease in luciferase expres-
sion in B cells compared to the empty vector and approx-
imately 50% inhibition relative to the ORF control (Fig-
ure 4B). We consistently observed a 40–50% inhibition of
luciferase expression in B cells using varying amounts of
plasmid DNA (0.1, 0.5, 1 and 2 g) (Figure 4B and data
not shown) indicating that repression was reproducible. We
also carried out luciferase reporter assays in the osteosar-
coma cell line U20S and detected a 54% and 56% inhibition
of luciferase expression compared to the ORF using 0.1 and
0.2 g of plasmid, respectively. Our data therefore point to
the 3′UTR of RGC-32 as a key controller of RGC-32 trans-
lation and indicate that repression of RGC-32 expression by
the 3′UTR may not be B cell specific.
A Pumilio binding element in the RGC-32 3′UTR is required
for gene repression
To identify putative cis acting motifs that could be respon-
sible for translational repression mediated by the RGC-32
3′UTR, we carried out in silico analysis. We identified two
AU-rich elements, four putative Pumilio binding elements
(PBE), and one cytoplasmic polyadenylation element (Fig-
ure 4C). AU-rich elements can be bound bymultiple factors
to regulate message stability and degradation (44), so we ex-
amined the potential role of these elements in the repression
of gene expression by the RGC-32 3′UTR using a mutagen-
esis approach. We found that mutation of the two AU-rich
elements, either individually or together, had no effect on
RGC-32 3′UTR-mediated repression of reporter gene ex-
pression (Supplementary Figure S6).
Since Puf family proteins are known translational repres-
sors of cell-cycle and survival mRNAs (21), we next exam-
ined the role of the PBEs in 3′UTR-mediated repression.
All of the putative PBEs contain the conserved 5′ core of
the 8 nucleotide Pumilio binding motif (45) (UGUA) with
some sequence variation 3′ to the core, as previously de-
scribed (23) (Figure 4C). PBE1 and PBE2 have mismatches
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Figure 6. Analysis of the role of PAS location in PBE-dependent repression via the 3′UTR. (A) Diagram showing the Renilla reporter construct generated
containing the additional U-rich and GU-rich downstream sequence element (DSE) located 3′ of the endogenous RGC-32 PAS and required for its usage.
(B) Luciferase reporter assays carried out as in Figure 5 to compare repression by theRGC-32 3′UTRwhen either the endogenous or downstream psicheck2
PAS are used. Control plasmids containing the RGC-32 ORF sequence or the GAPDH 3′UTR cloned downstream of the Renilla luciferase gene were
used. Data show Renilla luciferase signals normalised to the internal Firefly luciferase control and are expressed relative to the psicheck2 ORF luciferase
signal. The mean of two biological replicates -/+ standard deviation is shown. (C) Luciferase reporter assays analysing the effect of mutating PBE4 when
the endogenous RGC-32 PAS is used. (D) Sequence alignment of the products of a 3′RACE assay performed on the Renilla luciferase mRNA from the
transfection shown in (C), compared to the sequence obtained from 3′RACE analysis of the endogenous RGC-32 mRNA. (E) Luciferase reporter assays
using constructs where the endogenous RGC-32 PAS has been deleted in the context of the wild-type 3′UTR the mPBE4 3′UTR.
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at positions 6 and 8 of the PUM consensus motif (UGUA-
NAUA), PBE3 has a mismatch at position 6 and PBE4 has
a mismatch at position 7. Analysis using the Targetscan
database (http://www.targetscan.org/vert 71/) indicates that
the sequences of PBE1, PBE2 and PBE3 are completely
conserved across species and PBE4 is well conserved (some
species have aG in place of A at position 6).Wemutated the
conserved core sequence UGUA of each of the four PBEs
individually and examined the effect on RGC-32 3′UTR-
mediated repression (Figure 5A). Although mutation of
PBEs 1 and 2 had no effect on the ability of the RGC-
32 3′UTR to repress translation, mutation of PBE4 com-
pletely abolished repression (Figure 5B).Mutation of PBE3
reduced repression to approximately half that observedwith
the wild-type 3′UTR (Figure 5B). These data therefore indi-
cate that PBE4 is required for the repression of gene expres-
sion by the RGC-32 3′UTR and that PBE3 may also play
a role. The fact that PBE4 and PBE3 affect 3′UTR repres-
sion activity is consistent with the better matches of these
putative elements to the Pumilio consensus motif.
Interestingly, the PBE4 motif in the RGC-32 3′UTR is
located adjacent to the endogenous polyadenylation signal
(PAS) (Figure 4C). In fact PBE4 resembles a polyadenyla-
tion upstream element (USE) known to interact with the
cleavage factor Im (CFIm) and to be required for the proper
recognition of the PAS by the cleavage and polyadenyla-
tion factor (CPSF) (46,47). In the 3′UTR reporter exper-
iments described above, the endogenous PAS of RGC-32
was not used, with polyadenylation and cleavage directed by
the synthetic PAS of the plasmid. We therefore investigated
whether PBE4 was able to direct 3′UTR-mediated repres-
sion when the endogenous PAS of RGC-32 was active and
cleavage and polyadenylation factors were bound. An addi-
tional 3′ region of the RGC-32 gene that included a U-rich
and GU-rich DSE was therefore inserted into the reporter
construct to stimulate the use of the endogenous PAS (Fig-
ure 6A). Using 3′RACE and sequencing, we confirmed that
the insertion of the DSE led to usage of the endogenous
PAS and cleavage of the message at the same site as the en-
dogenous RGC-32 mRNA isolated from cells (Figure 6D).
We found that the insertion of the additional downstream
sequence and the use of the endogenous PAS did not affect
the ability of the RGC-32 3′UTR to repress reporter gene
expression (Figure 6B).
We next mutated PBE4 in the context of the longer RGC-
32 3′UTR reporter construct. Again, we found that muta-
tion of PBE4 led to a loss of RGC-32 3′UTR-mediated re-
pression (Figure 6C). Importantly, mutation of PBE4 did
not impair the usage of the endogenous PAS, since the
RGC-32 3′UTR was cleaved at the same site as the wild-
type 3′UTR containing construct and the endogenous mes-
sage (Figure 6D). PBE4 sequences do not therefore appear
to be required for the recognition or function of the endoge-
nous RGC-32 PAS. In fact, we found that RGC-32 3′UTR-
mediated repression was maintained when the endogenous
PAS was deleted, but PBE4 was left intact (Figure 6E).
Taken together, these results indicate that PBE4 is the
main mediator of repression directed by the RGC-32
3′UTR in this reporter assay. Importantly, despite its prox-
imity to the endogenous PAS, this PBE appears to function
independently of the PAS and can direct repression even
when a downstream PAS is used.
Puf family proteins are known to modulate translation
efficiency by interacting with deadenylases and regulating
the length of the polyA tail of their target transcripts (48–
50). We therefore investigated whether the loss of transla-
tional repression observed as a result of the mutation of
PBE4 had any effect on polyadenylation by using extension
polyA test (ePAT) assays to determine length of the polyA
tail present on reporter mRNAs. Gel-based analysis of the
size of the PCRproduct produced in ePAT assays compared
to the size of the PCR product amplified from the 3′UTR
cleavage site (no polyA, A0), revealed that the reporter tran-
scripts produced in the presence of the RGC-32 3′UTR had
very short polyA tails of 12–32 nucleotides in length (Figure
7A). However, when PBE4 was mutated, polyA tail length
increased to a range of polyA lengths between 32 and 82
nucleotides (Figure 7A). These data therefore indicate that
translational repression via PBE4 correlates with the pres-
ence of a short polyA tail and link translational repression
via the RGC-32 3′UTR with deadenylation. Since CPEB
can be a functional partner of Pumilio (48,51) and is in-
volved in regulating polyA tail length, we next examined
whether the putative CPE we identified through in silico
analysis was also required for translational repressionmedi-
ated by the RGC-32 3′UTR. Our results demonstrated that
mutagenesis of the CPE in the wild type RGC-32 3′UTR
had no effect on the ability of the 3′UTR to direct repres-
sion, indicating that the CPE is not required for 3′UTR-
mediated repression (Figure 7B and C). Consistent with
these observations, no further relief of repression was ob-
served when the CPE was mutated in the context of the
3′UTR containing the PBE4 mutation (Figure 7C). These
data indicate that CPEB binding to this CPE is not involved
in PBE4-dependent repression.
Since co-operation between Pumilio proteins and miR-
NAs has been shown to play a role in regulating transla-
tional repression in different cellular contexts (52,53), we
also examined the potential role of host cell miRNAs in
the regulation of RGC-32 translation. We used a number
of prediction programmes to identify host miRNAs that
may target RGC-32. The miR-30 family (miR-30a, b, c, d,
e) were the only miRNAs identified by most programmes
used (Supplementary Figure S7A). Interestingly, a previous
microarray analysis detected lower miR-30c and miR-30d
expression in latency III cell lines compared to latency I or
EBV-negative cells (54). We therefore investigated whether
miR30-c and miR30-d were able to repress reporter gene
expression via the RGC-32 3′UTR when they were trans-
fected into cells. We found that these miRs reduced reporter
gene expression in the presence of the RGC-32 3′UTR by
32% and 43%, respectively, when compared to a control re-
porter construct containing the RGC-32 ORF (Supplemen-
tary Figure S7B). In contrast, miR-30 with a mutated seed
sequence did not repress reporter gene expression.However,
when we mutated the miR-30 target sequence in the RGC-
32 3′UTR reporter construct, we did not observe any loss
of 3′UTRmediated repression in our transient transfection
assays (Figure S7C). We were also unable to detect any dif-
ferences in miR-30c or miR-30d expression between latency
I and latency III cells using sensitive Taqman PCRassays, in
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Figure 7. Analysis of the effects of RGC-32 3′UTR-mediated repression
on polyadenylation. (A) ePAT assay to measure poly A tail length per-
formed on Renilla luciferase mRNAs carrying the wild-type RGC-32
3′UTR or the PBE4 mutant 3′UTR from the experiments shown in Fig-
ure 6C. Control ePAT assays were performed on the endogenous GAPDH
mRNA. The A0 PCR amplicon comprises the 100 bp 3′end of the RGC-
32 or GAPDH 3′UTRs (no poly A tail). The position of the 100 and 200
bp DNA markers is indicated. (B) Diagram of the CPE and PBE4 mutant
RGC-32 3′UTR psicheck 2 luciferase constructs generated by site-directed
mutagenesis. (C) Luciferase assays using mCPE, mPBE and double mu-
tant 3′UTR (mCPE/mPBE) luciferase constructs carried out as described
in Figure 6.
contrast to the previous microarray-based study (data not
shown). We therefore conclude that the miR-30 family have
the potential to repress RGC-32 expression, but are not the
main mediators of RGC-32 3′UTR directed repression in
the B cells used in our assays.
Following our identification of Pumilio proteins as reg-
ulators of RGC-32 translation, we examined whether dif-
ferential expression of Pumilio proteins could explain the
differential expression of RGC-32 in latency I and latency
III cells. Although we found that levels of Pumilio 1 and
Figure 8. Analysis of Pumilio expression and Pumilio binding in B cell
lines. (A) Western blot analysis of Pumilio 1 and Pumilio 2 protein expres-
sion in EBV negative (–ve), EBV-infected latency I (I) and latency III (III)
cell lines. Actin levels serve as a loading control. (B) RNA immunopre-
cipitation analysis using anti-Pumilio 1 antibodies in cross-linked Mutu I
(latency 1) and Mutu III (latency III) cell lines. Precipitated RNA was re-
verse transcribed and analysed byQPCR against a standard curve of RNA
extracted from an input sample from each cell line. Percentage input values
for each Pumilio 1 immunopreciptationwere divided by signals obtained in
the IgG control immunoprecipitation and then normalised to background
enrichment for a non-target mRNA (GAPDH). Cyclin B is a known tar-
get of Pumilio and was used as a positive control for mRNA binding. Data
show the mean ± standard deviation of two independent experiments. (C)
RNA immunoprecipitation for Pumilio 1 carried out in Akata (latency I)
and GM12878 (latency III) cells as in (B).
Pumilio 2 varied across different cell lines, Pumilio proteins
were not expressed at lower levels in latency III cells where
RGC-32 protein expression is expressed (Figure 8A). Since
Pumilio binding can be regulated by its association with
other proteins and in response to different signals, we next
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examined whether Pumilio binding to the RGC-32 mRNA
was differentially regulated in latency I and latency III cells
usingRNA immunoprecipitation assays. Because of the dif-
ferent sensitivities of latency I and latency III cell lines to ly-
sis conditions, we performed these assays in crosslinked cells
to preserve RNA-protein interactions in both cell types. We
found that available Pumilio 2 antibodies did not effectively
precipitate Pumilio 2 in these assays, so we were only able
to analyse the level of endogenous RGC-32 mRNA precip-
itated using Pumilio 1 antibodies. Our data demonstrated
that RGC-32 mRNA showed 2.5–3-fold lower enrichment
in Pumilio 1 immunoprecipitations from latency III cells
compared to latency I cells indicative of reduced Pumilio 1
binding (Figure 8B and C). This is consistent with the in-
creased translation of RGC-32 mRNA in latency III cell
lines. RGC-32 mRNA enrichment was similar or higher
than the enrichment observed for the known Pumilio target
mRNA cyclin B (25). Interestingly, our data demonstrated
that Pumilio 1 binding to cyclin B was also reduced in la-
tency III suggesting that the differential Pumilio 1 binding
observed between these two cell types may not be RGC-
32 specific. Although we detected differential binding of
Pumilio 1 to cyclin B mRNA we found that cyclin B pro-
tein levels were similar in the latency I and latency III cell
lines we investigated here (data not shown). Cyclin B levels
are known to be transcriptionally regulated in EBV-infected
cells and can also be regulated as a result of the disruption
of the G2/M checkpoint by EBV-encoded latent and lytic
cycle proteins so exactly how altered Pumilio binding may
affect cyclin B translation is unclear (55–57). Further inves-
tigation of cyclin B regulation is however beyond the scope
of the current study. Our data however indicate that reduced
binding of Pumilio to the RGC-32 3′UTR may play a role
in the activation of RGC-32 translation in latency III cell
lines.
To determine whether Pumilio proteins were required for
translational repression of RGC-32 in vivo, we knocked-
down Pumilio 1 and Pumilio 2 expression in both latency
I and latency III cell-lines using a pool of specific siRNAs.
We found that Pumilio knock-down resulted in an up to
3.6-fold increase in RGC-32 protein expression in latency
III cells (Figure 9A and B). It therefore appears that even
though RGC-32 protein is expressed in latency III cells, a
component of Pumilio-mediated repression is still present.
This repression can be relieved by reducing Pumilio 1 and 2
expression, providing further evidence for the role of these
proteins as controllers of RGC-32 translation. Interestingly,
reducing Pumilio protein expression did not lead to the ex-
pression of RGC-32 protein in latency I cells (Figure 9C and
D). We hypothesise that in latency I cells, Pumilio proteins
initiate a translational repression event that leads to the se-
questration of the RGC-32 mRNA in an inactive complex
or granule that may no longer be Pumilio-dependent and
may involve association with other RBPs. This hypothesis
may explain why high levels of RGC-32mRNAare detected
in latency I cells.We next examinedwhether Pumilio knock-
down in latency III cells resulted in an increase in polyA
tail length. Consistent with our observations using the PBE
4 mutant 3′UTR in reporter assays, we found that knock-
down of Pumilio proteins led to the appearance of endoge-
nous RGC-32 mRNA species with longer polyA tails (Fig-
ure 10). These data therefore confirm the relationship be-
tween Pumilio-mediated RGC-32 translational repression
and the presence of a short polyA tail.
DISCUSSION
RGC-32 plays a key role in cell cycle regulation and is dereg-
ulated in numerous tumour contexts. We now show that
RGC-32 is upregulated on infection of resting B cells by
EBVand that a reduction in the expression ofRGC-32 leads
to the death of EBV-infected cells. These data therefore pro-
vide the first evidence that RGC-32 expression plays an im-
portant role in promoting the survival of EBV-immortalised
cells. EBV is known to deregulate multiple cell-cycle check-
points, including the G2/M checkpoint and we previously
showed that RGC-32 overexpression in B cells leads to
G2/M checkpoint disruption (15). Our data now indicate
that cell-cycle regulation by RGC-32 through its role as a
CDK1 activator and/or PLK1 binding protein may be cru-
cial for the growth and survival of EBV-infected cells.
Intriguingly, RGC-32 upregulation on EBV infection of
naı¨ve B cells seems to be mediated through the relief of
translational repression and occurs despite a significant re-
duction in RGC-32 mRNA expression, consistent with our
previous observations in EBV negative and EBV-infected
cell lines (15). We have now uncovered key aspects of the
mechanism of this translational repression. We show that
RGC-32 mRNA is associated with actively elongating ri-
bosomes even when its translation is repressed, indicative
of repression at a post-initiation stage, or perhaps simulta-
neous inhibition of both initiation and elongation that we
would be unable to detect in our assays. We demonstrate
that RGC-32 mRNA, like many cell-cycle gene mRNAs, is
a target for Pumilio repressor proteins. Pumilio-mediated
repression via the RGC-32 3′UTR is dependent on the pres-
ence of a single Pumilio binding site in the RGC-32 3′UTR
located immediately upstream of the PAS. It is interesting
that the speedy/RINGO family of atypical CDK activa-
tors are also translationally repressed through the binding
of Pumilio proteins to their 3′UTRs, indicating a common
mode of regulation between CDK activators across differ-
ent species.
We also found that Pumilio-mediated repression corre-
lated with the presence of a short poly A tail in reporter
assays. Mutation of the essential PBE (PBE 4) in the RGC-
32 3′UTR led to polyA tail lengthening of reporter mR-
NAs and Pumilio 1 and 2 depletion in cells led to increased
RGC-32 protein expression in latency III cells and the ap-
pearance of a longer polyA tail on the endogenous RGC-
32 mRNA. Our data therefore demonstrate that Pumilio-
mediated repression is associated with deadenylation. Like
their C.elegans, Drosophila and yeast PUF counterparts,
human Pumilio proteins are known to repress translation
in a manner that correlates with shortening of mRNA
polyA tails and involves recruitment of deadenylases (49).
Human Pumilio 1 and 2 proteins promote deadenylation
through their association with the CCR4-NOT deadeny-
lase complex which contains multiple subunits related to
the PUF-associated yeast Pop2p and CCR4p deadenylases
(21,49). In yeast, PUF-mediated deadenylation and decap-
ping promotes mRNA degradation (58–60). The repression
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Figure 9. The effect of Pumilio depletion on endogenous RGC-32 expression. (A) Silencing of Pumilio 1 and Pumilio 2 expression in the EBV-positive
GM12878 LCL (latency III) using 500 nM of non targeting control siRNA or 200 or 500 nM of a mix of Pumilio 1 and Pumilio 2 siRNAs. Cells were
harvested 48 h post transfection and analysed by western blotting for Pumilio 1, Pumilio 2, RGC-32 and actin (loading control). (B) Quantification of the
Western blot results of two independent depletion experiments in GM12878 cells. Pumilio and RGC-32 signals were normalised to the actin control and
then expressed relative to the level of expression in the cells transfected with the scrambled siRNA control. Data show the mean ± standard deviation of
two independent depletion experiments. (C) Silencing of Pumilio 1 and Pumilio 2 expression in the EBV-positive Elijah BL line (latency I) using a mix of
siRNAs. Cells were transfected with siRNAs, incubated for 24 h and then re-transfected with more siRNAs and harvested after a further 24 h to achieve
optimal depletion. Pumilio 1, Pumilio 2 and actin levels were determined by western blotting. Samples were re-analysed for RGC-32 expression alongside
a positive control for RGC-32 expression (LCL). (D) Quantification of the western blot results of two independent depletion experiments in Elijah cells as
in (B).
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Figure 10. The effects of Pumilio depletion on polyadenylation of the en-
dogenous RGC-32 mRNA. (A) ePAT analysis of the length of the endoge-
nousRGC-32mRNApolyA tail in unstransfected (Unt)GM12878 latency
III cells, and in cells transfected with non targeting control siRNA (500
nM) or 200 nM of a 1:1 mix of Pumilio 1 and Pumilio 2 siRNAs. ePAT
analysis of the polyA tail of the endogenous GAPDH mRNA was also
measured as a control. (B) ImageJ quantitation of the agarose gels shown
in (A). The areas boxed by dotted lines show the size of the most abun-
dant polyadenylatedmRNA species. The arrow shows theRGC-32mRNA
species with a longer polyA tail detected in cells transfected with Pumilio
targeting siRNAs.
of RGC-32 translation we observe in EBV negative and la-
tency I cell-lines however, does not appear to correlate with
mRNA degradation, since RGC-32 mRNA levels are con-
siderably higher in these cell-lines and in primary B cells
compared to newly-infected B cells or latency III cell lines
where RGC-32 is translated.
Pumilio proteins have however also been demonstrated to
repress translation initiation and elongation. Repression of
translation initiation may result from the effects of dead-
enylation on polyA tail interactions with the translation
initiation machinery in the closed-loop initiation model.
Pumilio-mediated inhibition of translation initiation may
however also occur through competition with eIF4E for
binding to the 7-methyl guanosine cap or by binding to and
antagonising the function of polyA binding protein (PABP)
in closed-loop translation (50,61). Our observations of the
continued association of RGC-32 with polysomes in cells
where its translation is repressed is however not consis-
tent with a Pumilio-directed block to translation initia-
tion mediated by either deadenylation or other mecha-
nisms. Interestingly, C.elegans and mammalian PUF pro-
teins have also been found to repress translation elonga-
tion through their associationwith themiRNAbinding pro-
tein Argonaute (Ago) and the translation initiation factor,
eIF1A (62). However, Ago proteins were found by another
group to be dispensable for Pumilio-mediated repression by
Drosophila and human PUFs in vivo (50). It is therefore pos-
sible that Pumilio-mediated repression of RGC-32 leads to
the repression of translation elongation, but further work
will be needed to determine whether this is Ago-dependent
and involves any effects on eIF1A activity. It was recently
demonstrated that deadenylation can be a secondary event
in Pumilio-mediated repression (50). This study, using the
RNA binding domain of Pumilio 2, found that despite
the clear association between Pumilio-dependent repres-
sion and polyA tail shortening, repression was not depen-
dent on deadenylases. Repression was however dependent
on PABP. The experiments we have conducted to date can-
not distinguish whether deadenylation is a cause or conse-
quence of translational repression and perhaps the contin-
ued association of RGC-32 mRNA with polysomes points
to a deadenylation-independentmechanism, but this will re-
quire further investigation.
Interestingly, we observe no differences in the total lev-
els of Pumilio 1 and 2 in the B cell lines where RGC-32 is
differentially translated, so downregulation of Pumilio ex-
pression does not appear to explain the relief of transla-
tional repression in EBV-infected latency III cell lines. We
do however detect decreased binding of Pumilio 1 to both
the RGC-32 and cyclin B mRNAs in latency III compared
to latency I cells. This indicates that the ability of Pumilio
to bind to target mRNAs is differentially controlled in EBV
infected cells. How Pumilio bindingmay be regulated in this
context is however unknown. Pumilio proteins often func-
tion in conjunction with other RNA-binding proteins like
CPEB, Nanos and deleted in azoospermia-like (DAZL) in
the repression of a variety of mRNAs (26,63,64) so it is
possible that alterations in the levels or activity of other
factors or their interactions with Pumilio are responsible
for this differential binding. Identifying these putative co-
operative partners will require further studies that could in-
clude screening of some known candidates, but unbiased
proteomics approaches may be most informative. Pumilio
1 function can also be regulated by phosphorylation, with
phosphorylation coinciding with the loss of its interaction
with CPEB, so it is possible that Pumilio binding may be
differentially regulated in EBV infected cells through effects
on phosphorylation.
Pumilio proteins are also known to co-operate with miR-
NAs in the regulation of translation. For example, Pumilio
1 and 2 binding to the pre-mRNA encoding the cyclin-
dependent kinase inhibitor p27 induces a conformational
change required for miR-221 and miR-222-mediated re-
Downloaded from https://academic.oup.com/nar/advance-article-abstract/doi/10.1093/nar/gky038/4827088
by Sussex Language Institute user
on 30 January 2018
Nucleic Acids Research, 2018 17
pression (53). Pumilio binding to the 3′UTR of the E2F3
oncogene also enhances targeting bymultiplemiRNAs (52).
Genome-wide studies have found that miRNAbinding sites
are enriched in Pumilio-targeted mRNAs with PBEs clus-
tered around predicted miRNA binding sites (24,65). Con-
sistent with the observations for the p27 pre-mRNA, mes-
sages with PBEs and miRNA binding sites in close proxim-
ity were found to be more likely to form stable secondary
structures that can presumably be disrupted by Pumilio
binding (65). We found that the miR-30 family of miRNAs
were predicted to target the 3′UTR of RGC-32. Since previ-
ous microarray-based analysis had indicated that members
of themiR-30 family were downregulated in latency III cells
compared to latency I cells or EBV-negative cells, we exam-
ined the role of these miRs in RGC-32 translation control.
Although we found that miR-30c and miR-30d could di-
rect translational repression via the RGC-32 3′UTR in re-
porter assays, mutation of the miR-30 binding site in the
RGC-32 3′UTR did not relieve repression mediated by the
RGC-32 3′UTR. Mutation of this site did not therefore af-
fect Pumilio-mediated repression. We were also not able to
confirm previously published reports (54) of miR-30c or
miR-30d downregulation in the latency III cell lines we ex-
amined. It is therefore possible that this miR family may
play a role in regulating RGC-32 translation in certain cir-
cumstances, but they do not appear to co-operate in the
Pumilio-mediated repression we observe here. EBV also en-
codes a number of viral miRNAs that could potentially play
a role in RGC-32 regulation, but these miRNAs are either
expressed at similar levels in latency I and latency III cells
or are upregulated in latency III cells (66). This pattern of
expression is the opposite expected for a directly-targeting
miRNA, given that we observe activation of RGC-32 trans-
lation in latency III cells. We did not therefore investigate
any potential role for these miRNAs in RGC-32 regulation.
An important question that remains outstanding con-
cerns which EBV latent protein(s) expressed in latency III
cells may mediate the changes in the host cell that leads
to RGC-32 translational activation. On EBV infection, im-
mortalised cells express the full panel of EBV latent genes
that include the latent membrane proteins LMP1, 2A and
2B and the nuclear proteins EBNA-leader-protein, EBNA
1, EBNA 2, EBNA 3A, EBNA 3B and EBNA 3C. LMPs
function as constitutively active receptors and activate mul-
tiple signalling pathways in infected cells and the EBNAs
function as regulators of viral and cellular transcription. It
will be interesting to determine whether the activity of one
ormore of these proteins is required to trigger the activation
of RGC-32 translation through their effects on signalling or
host gene expression. Infection experiments using mutant
viruses and cell lines expressing individual latent proteins
would be useful for future studies to elucidate this.
An interesting observation of our work concerns our in-
ability to relieve the repression of RGC-32 translation by
Pumilio protein depletion in latency I cells. This is despite
our ability to increase RGC-32 translation through Pumilio
depletion in latency III cells presumably through relief of
some residual repression. This led us to propose that RGC-
32 mRNAmay be compartmentalised in a highly repressed
state in latency I cells, with Pumilio depletion no longer suf-
ficient to relieve repression. This repression likely involves
additional as yet unidentified factors. Pumilio proteins are
known to localise to granules containing translationally re-
pressed mRNAs (67,68) so it is possible that Pumilio ini-
tiates a repression mechanism that involves sequestration
of RGC-32 mRNA into cytoplasmic RNA granules where
translation is repressed, e.g. stress granules. Consistent with
our observations of repression through regulation of elon-
gation, dendritic RNA granules have been found to con-
tain stalled polysomes which can be reactivated rapidly (69).
In preliminary immunofluorescence analysis, we have de-
tected the presence of Pumilio proteins in granules in both
latency I and latency III cells, but further studies are re-
quired to determine whether RGC-32 mRNA is present in
these granules and potentially released on translational ac-
tivation during infection. These experiments will be partic-
ularly challenging given the low levels of RGC-32 mRNA
in the latency III cells in which the protein is translated.
In summary, we show that expression of the atypi-
cal CDK activator RGC-32 is induced on EBV infec-
tion of resting B cells and is essential for the growth of
EBV-infected cells. RGC-32 protein expression is activated
through the relief of translation repression, rather than
through a transcriptional mechanism, a phenomenon not
previously described for primary EBV infection. We reveal
that the repression of RGC-32 translation is mediated by
theRNA-binding protein Pumilio, is dependent on the pres-
ence of a single binding site for Pumilio in the 3′UTR and
is associated with deadenylation of the RGC-32 polyA tail.
Our results therefore identify a newway in which the expres-
sion ofRGC-32 can be controlled that is likely to be relevant
for the study of RGC-32 deregulation in numerous tumour
contexts.
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